Skip to main content
SpringerLink
Log in

Anti-TNFα agents: ulcerative colitis or Crohn's disease

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Korzenik J, et al. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Alimentary Pharmacology and Therapeutics : 2 Jul 2019. Available from: URL: http://doi.org/10.1111/apt.15370

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-TNFα agents: ulcerative colitis or Crohn's disease. Reactions Weekly 1763, 7 (2019). https://doi.org/10.1007/s40278-019-65099-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-65099-5

Search

Navigation